Redwood Investment Management’s Quest Diagnostics DGX Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2023
Q2
Sell
-10,994
Closed -$1.55M 240
2023
Q1
$1.55M Buy
10,994
+1,537
+16% +$220K 0.17% 186
2022
Q4
$1.48M Buy
+9,457
New +$1.36M 0.2% 167
2022
Q3
Sell
-43,085
Closed -$5.73M 228
2022
Q2
$5.73M Buy
43,085
+6,614
+18% +$901K 0.97% 29
2022
Q1
$4.99M Buy
36,471
+2,119
+6% +$295K 0.74% 36
2021
Q4
$5.94M Buy
34,352
+26,931
+363% +$4.1M 0.78% 36
2021
Q3
$1.08M Buy
7,421
+5,208
+235% +$762K 0.15% 207
2021
Q2
$292K Sell
2,213
-4,538
-67% -$594K 0.05% 241
2021
Q1
$862K Buy
+6,751
New +$832K 0.16% 200
2020
Q3
Sell
-7,485
Closed -$853K 260
2020
Q2
$853K Buy
+7,485
New +$794K 0.24% 83

Other funds holding DGX

Redwood Investment Management's DGX Position: Q2 2023 in Review

Redwood Investment Management sold out of Quest Diagnostics (DGX) in Q2 2023, closing a stake of 10,994 shares — an estimated $1.55M sold.

Redwood Investment Management first reported a position in DGX in Q2 2020 and held it in 9 quarters. The position peaked at $5.94M in Q4 2021. 820 funds tracked by Wall St. Rank hold DGX as of Q2 2023.

  • Redwood Investment Management reported no remaining Quest Diagnostics position as of Q2 2023 after selling out during the quarter.
  • Redwood Investment Management sold 10,994 Quest Diagnostics shares in Q2 2023, an estimated $1.55M.
  • Redwood Investment Management first reported a position in Quest Diagnostics in Q2 2020 and held it in 9 quarters.
  • Redwood Investment Management's Quest Diagnostics position peaked at $5.94M in Q4 2021.
  • 820 funds tracked by Wall St. Rank held Quest Diagnostics as of Q2 2023.

Based on Redwood Investment Management's 13F filing for Q2 2023, filed 15 Aug 2023.